The Journal
of the American Heart Association on February 18 retracted an
article by Dharma Bhatta and Stanton Glantz.
As I documented earlier, Bhatta
and Glantz published demonstrably false
findings. Details of the retraction were reported by USA Today’s Jayne
O’Donnell,
Ivan Oransky at
Retraction Watch
and Alex Norcia of
Vice,
among others.
The
Bhatta-Glantz article states that “This work was supported by grants
R01DA043950 from the National Institute on Drug Abuse, P50CA180890 from the National
Cancer Institute and the Food and Drug Administration Center for Tobacco
Products, U54HL147127 from the National Heart, Lung, and Blood Institute and
the Food and Drug Administration Center for Tobacco Products.” Those grants, itemized below (Source, NIH RePORTER), probably funded
additional research beyond the flawed vape heart attack study.
Federal Support of Retracted JAHA Article By Dharma Bhatta and Stanton Glantz | ||||
---|---|---|---|---|
Federal Grant Number | 2017 | 2018 | 2019 | All Years |
R01DA043950 | $511,397 | $526,209 | $541,346 | $1,578,952 |
P50CA180890 | $3,829,020 | $155,362 | --- | $3,984,382 |
U54HL147127 | --- | $4,000,000 | $4,000,000 | $8,000,000 |
All | $4,340,417 | $4,681,571 | $4,541,346 | $13,563,334 |
The
$13.6 million are termed “direct costs,” the amount of money Dr. Glantz was
awarded to conduct his research. Each
university negotiates an additional payment from NIH for facility and
administrative (F&A) costs. The rate
for UCSF during the period was about 59%. That means the federal government paid UCSF
as much as $8 million more, a significant sum.
Still,
that $13.6 million was only a fraction of the $51 million funneled from the
National Institutes of Health to Glantz since 2005. That funding supported 292 Glantz articles recorded
in PubMed.
The next chart, courtesy of Clive Bates, illustrates Glantz's annual NIH funding since 1985. Note the significant increase in 2013, which reflects the start of massive transfers from FDA to NIH of hundreds of millions in tobacco company user fees.
The next chart, courtesy of Clive Bates, illustrates Glantz's annual NIH funding since 1985. Note the significant increase in 2013, which reflects the start of massive transfers from FDA to NIH of hundreds of millions in tobacco company user fees.
This
body of taxpayer-supported work, universally anti-tobacco, anti-harm-reduction,
is in keeping with the government’s stated objective “to create a world free of tobacco use.” This prohibitionist mission supports
thousands of NIH-funded researchers, and cows countless more into silence when
they could be producing life-saving harm reduction data and analyses.
A
true public health agenda would include federal support for honest research
aimed at prolonging healthy lives, regardless of lifestyle.
No comments:
Post a Comment